AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal
8 months, 1 week ago

AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Drugs giant AstraZeneca has promised to hand more money out to shareholders, ahead of a vote on whether to increase the pay deal for its boss to up to £18.7 million. This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca's investment proposition for shareholders Michel Demare, chairman of AstraZeneca Michel Demare, chairman of AstraZeneca, said: “The board is delighted to announce a 7% increase to the dividend. “This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders.” AstraZeneca’s profits more than doubled in 2023 after strong sales of its cancer treatments. One of the firm’s top shareholders, GQG Partners, said earlier this week that Mr Soriot was “massively underpaid” and deserved the potential pay hike.

Shareholders Pay Dividend Increase Astrazeneca Pay Deal  line  deal  ahead  emails  promises  free  187m  increase  sign  breaking  vote  astrazeneca  chiefs  shareholders  rise  pay  dividend

History of this topic

Is any CEO worth the £18.7m AstraZeneca wants to pay boss Pascal Soriot?
8 months, 1 week ago

Is any CEO worth the £18.7m AstraZeneca wants to pay boss Pascal Soriot?

The Independent  

Is any employee worth paying £18.7m? The results are somewhat less impressive over the last year, during which AstraZeneca’s share price has declined by 6.5 per cent while the FTSE 100 has improved by 2 per cent. Luke Hildyard, of the High Pay Centre, argues that Soriot – a professional manager, not an entrepreneur risking his own money to create …

AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal
8 months, 1 week ago

AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal

The Telegraph  

AstraZeneca has suffered an investor backlash over a £19m pay award for its chief executive, in a vote that will deepen concerns of an exodus of UK companies to the US. Investor advisory groups had labelled Mr Soriot’s pay deal “excessive” ahead of the vote and the executive’s remuneration has become a flashpoint in a broader debate about how much …

AstraZeneca chief exec Pascal Soriot earns £120m in 10 years
1 year, 10 months ago

AstraZeneca chief exec Pascal Soriot earns £120m in 10 years

Daily Mail  

Astrazeneca boss Pascal Soriot scooped £15.3million in pay last year, taking his total earnings to almost £120million in a little over a decade at the pharmaceuticals giant. A pay award of £15million, taking Soriot’s total pay over the past ten years to over £100million, is a highly unusual amount for someone who is just a manager of a long-established organisation, …

ALEX BRUMMER: Astrazeneca boss Pascal Soriot faces an unjust vote
3 years, 7 months ago

ALEX BRUMMER: Astrazeneca boss Pascal Soriot faces an unjust vote

Daily Mail  

AstraZeneca and the Oxford vaccine may be the toast of great swathes of the United Kingdom, but the City’s governance mavens take a different view. The fact that chief executive Pascal Soriot grasped the nettle and developed a cost price, easily stored and transported vaccine for the whole world has done it no good with advisory services, which monitor pay …

Discover Related